# US 2010/0166758 A1 · Novel antibody molecules and nucleic acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166758 A1
- Document ID: US20100166758A1
- Status: Published application
- Kind: A1
- Application number: 12/719,049
- Filed: 2010-03-08
- Published: 2010-07-01
- Earliest claimed: 2007-04-27
- Inventors: James Burnie; Philipp Wechner
- Web page: https://patentgrep.com/patent/US20100166758A1

## CPC

- C07K 16/14: against material from fungi, algea or lichens
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/18: against material from animals or humans
- A61K 2039/505: {comprising antibodies}
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/21: containing a His-tag
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An scFv peptide comprising a VH domain and a VL domain linked by an amino acid spacer is disclosed. The VH domain comprises a sequence with at least 80% sequence identity to the sequence of SEQ ID NO. 64. The VL domain comprises a sequence with at least 80% sequence identity to the sequence of SEQ ID NO. 66. The scFv peptide also comprises the substitution or deletion of an amino acid in the VH domain at the position corresponding to C28.

## Claims

### Claim 1

An scFv peptide comprising a VH domain and a VL domain, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:64 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:66, and wherein the scFv peptide comprises a substitution of an amino acid in the VH domain at the position corresponding to C28 of SEQ ID NO:64.

### Claim 2 (depends on 1)

The scFv peptide according to claim 1, wherein the substitution of the amino acid in the VH domain is C28Y.

### Claim 3 (depends on 1)

The scFv peptide according to claim 1, wherein the substitution of the amino acid in the VH domain is C28S.

### Claim 4 (depends on 1)

The scFv peptide according to claim 1, wherein an amino acid spacer links the VH domain and the VL domain.

### Claim 5

An scFv peptide, comprising an amino acid sequence selected from the group consisting of SEQ ID NO:8, 10 and 14, wherein Xaa denotes an amino acid residue other than cysteine and wherein the N-terminal methionine residue may optionally be cleaved off.

### Claim 6

An scFv peptide comprising the amino acid sequence as set forth in SEQ ID NO:10, wherein Xaa is tyrosine or serine and wherein the N-terminal methionine residue may optionally be cleaved off.

### Claim 7 (depends on 6)

The scFv peptide of claim 6, wherein said scFv peptide is encoded by a nucleic acid sequence having (taa)2 located at the 3′ end of said nucleic acid sequence.

### Claim 8 (depends on 6)

A pharmaceutical composition comprising the scFv peptide according to claim 6 in combination with a pharmaceutically acceptable excipient, diluent or carrier.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, further comprising an antifungal agent.

### Claim 10 (depends on 1)

A nucleic acid molecule comprising a nucleic acid sequence encoding the scFv peptide according to claim 1.

### Claim 11 (depends on 10)

The nucleic acid molecule according to claim 10, further comprising the sequence (taa)n located at the 3′ end of the sequence encoding the scFv peptide wherein n is 1 or 2.

### Claim 12 (depends on 10)

The nucleic acid molecule according to claim 10, wherein the molecule comprises a nucleic acid sequence selected from the group consisting of: SEQ ID NO:7, 9 and 13, wherein nnn denotes a codon coding for an amino acid other than a cysteine residue.

### Claim 13 (depends on 10)

A vector molecule comprising the nucleic acid molecule according to claim 10.

### Claim 14 (depends on 13)

A host cell comprising the vector molecule according to claim 13.

### Claim 15 (depends on 10)

A method for producing a scFv peptide, comprising culturing a host cell having incorporated therein an expression vector containing, under control of suitable transcriptional control elements, the nucleic acid molecule according to claim 10 under conditions sufficient for expression of said peptide in the host cell thereby causing the production of said peptide and recovering the peptide produced by said host cell.

### Claim 16 (depends on 1)

A method of treating a fungal infection, comprising administering to a patient in need thereof an effective amount of the scFv peptide according to claim 1.

### Claim 17 (depends on 16)

The method according to claim 16, further comprising the step of administering to the patient an effective amount of an antifungal agent.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the antifungal agent is an azole antifungal agent, a polyene antifungal agent or an echinocandin antifungal agent.

### Claim 19 (depends on 6)

A method of treating a fungal infection, comprising administering to a patient in need thereof an effective amount of the scFv peptide according to claim 6.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the fungal infection is due to a Candida, Cryptococcus, Histoplasma, Aspergillus, Torulopsis, Mucormycosis, Blastomycosis, Coccidioidomycosis or Paracoccidioidomycosis organism.

### Claim 21 (depends on 19)

The method according to claim 19, further comprising administering to the patient an effective amount of at least one additional antifungal agent.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the at least one additional antifungal agent is an azole antifungal agent, a polyene antifungal agent or an echinocandin antifungal agent.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the at least one additional antifungal agent is an azole antifungal agent and wherein the azole antifungal agent is selected from the group consisting of: itraconazole, voriconazole isavuconazole, fluconazole, miconazole, ketoconazole, and posaconazole.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the azole antifungal agent is voriconazole.

### Claim 25 (depends on 21)

The method according to claim 21, wherein the at least one additional antifungal agent is a polyene antifungal agent, and wherein said polyene antifungal agent comprises amphotericin B or a derivative thereof.

### Claim 26 (depends on 21)

The method according to claim 21, wherein the at least one additional antifungal agent is an echinocandin antifungal agent, and wherein said echinocandin antifungal agent is caspofungin.